2015 Fiscal Year Final Research Report
Creation of novel anticancer lead compounds targeting receptor-type tyrosine kinase Met molecule
| Project/Area Number |
25460156
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Tokyo University of Science |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKASAWA Ryoko 東京理科大学, 薬学部・薬学科, 講師 (10398828)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 医薬分子設計 / 癌 / Met / チロシンキナーゼ阻害剤 / in silico分子設計 / ペプチド / アロステリック部位 / アポトーシス |
|---|
| Outline of Final Research Achievements |
The receptor-type tyrosine kinase Met, which is known to involved in the many steps of cancer growth and development, is an attractive molecular target for the creation of new anticancer drugs. In this study, we attempted to create new small molecular inhibitors through the most optimized-binding peptide as a design-chip, which is designed by using inactive form of Met. Interestingly, we could discover novel inhibitors, which bind to the allosteric site of Met molecule.
|
| Free Research Field |
生化学・分子生化学
|
